NCT03340675Phase 2Completed

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

Study sponsor: Cumberland Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-03-06Actual
Enrollment · participants46Actual
Source updated2026-03-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of Treatment-Emergent Adverse Events (Safety & Tolerability). After: Measure: Incidence of Treatment-Emergent Adverse Events.

Check registry source

· 5 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of Treatment-Emergent Adverse Events (safety & tolerability). After: Measure: Incidence of Treatment-Emergent Adverse Events (Safety & Tolerability).

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 48 participants (planned). After: 46 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Sep 2025. After: 6 Mar 2024.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview